Based on ratings from 5 stock analysts, the TG Therapeutics Inc stock price is expected to increase by 39.42% in 12 months. This is calculated by using the average 12-month stock price forecast for TG Therapeutics Inc. The lowest target is $9 and the highest is $55. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assignedTGTX 5 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect TG Therapeutics Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on TGTX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of TGTX.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Tara Bancroft TD Cowen | Buy | $50 | Initiates | Oct 29, 2024 |
Edward White HC Wainwright & Co. | Buy | $49 | Reiterates | Sep 18, 2024 |
Mayank Mamtani B. Riley Securities | Buy | $34 | Maintains | Aug 7, 2024 |
Corinne Jenkins Goldman Sachs | Neutral | $20 | Maintains | Aug 7, 2024 |
Edward White HC Wainwright & Co. | Buy | $49 | Reiterates | Aug 6, 2024 |
Matthew Kaplan Ladenburg Thalmann | Buy | $40 | Maintains | May 2, 2024 |
Edward White HC Wainwright & Co. | Buy | $49 | Maintains | May 2, 2024 |
Edward White HC Wainwright & Co. | Buy | $45 | Reiterates | Apr 18, 2024 |
Eric Joseph JP Morgan | Overweight | $25 | Reiterates | Apr 18, 2024 |
Matthew Kaplan Ladenburg Thalmann | Buy | $39 | Reiterates | Apr 18, 2024 |
Edward White HC Wainwright & Co. | Buy | $45 | Reiterates | Mar 1, 2024 |
Corinne Jenkins Goldman Sachs | Neutral | $13 | Maintains | Feb 29, 2024 |
Edward White HC Wainwright & Co. | Buy | $45 | Reiterates | Feb 28, 2024 |
Mayank Mamtani B. Riley Securities | Buy | $29 | Maintains | Feb 5, 2024 |
Edward White HC Wainwright & Co. | Buy | $45 | Maintains | Jan 11, 2024 |
Matthew Andrews Jefferies | Buy | Maintains | Nov 1, 2023 | |
Eric Joseph JP Morgan | Overweight | $23 | Maintains | Nov 1, 2023 |
Mayank Mamtani B. Riley Securities | Buy | $24 | Maintains | Oct 20, 2023 |
Edward White HC Wainwright & Co. | Buy | $41 | Reiterates | Sep 18, 2023 |
Eric Joseph JP Morgan | Overweight | $22 | Maintains | Aug 7, 2023 |
When did it IPO
2010
Staff Count
300
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Michael S. Weiss Esq.
Market Cap
$3.77B
In 2023, TGTX generated $233.7M in revenue, which was a increase of 8,290.02% from the previous year. This can be seen as a signal that TGTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Meta and Oracle are among the top five stocks to watch this week, focusing on the artificial intelligence market.
Why It Matters - AI stocks like Meta and Oracle are gaining attention, indicating strong market interest and potential growth, which could influence investment decisions and stock performance.
Summary - TG Therapeutics, Inc. (NASDAQ: TGTX) will hold a conference call on November 4, 2024, at 8:30 AM ET to discuss Q3 2024 results and the business outlook for the year.
Why It Matters - The upcoming conference call will provide insights into TG Therapeutics' Q3 performance and future business strategy, influencing investor sentiment and stock valuation.
Summary - Investors are encouraged to explore stocks beyond Nvidia, Apple, and Tesla to identify opportunities for significant earnings growth.
Why It Matters - The mention of excluding major tech stocks like Nvidia, Apple, and Tesla suggests potential opportunities in lesser-known companies with high growth potential, indicating a shift in investment strategy.
Summary - TG Therapeutics shares reached new 52-week highs, bolstered by favorable Briumvi data at ECTRIMS, despite Roche's FDA approval of Ocrevus Zunovo, which is viewed as a minor growth opportunity.
Why It Matters - TG Therapeutics' stock surge reflects strong Briumvi data, indicating competitive positioning against Ocrevus Zunovo. This could signal growth potential and market confidence in Briumvi's efficacy and safety.
Summary - BRIUMVI showed an annualized relapse rate of 0.020 in year 5 of treatment, indicating one relapse every 50 years for patients.
Why It Matters - A low annualized relapse rate for BRIUMVI indicates strong efficacy, potentially driving higher demand, boosting sales, and positively impacting the company's stock value.
Summary - TG Therapeutics presented data at ECTRIMS 2024 showing that BRIUMVI infusions in RMS patients caused only mild reactions, and patients switching from anti-CD20 treatment had successful outcomes.
Why It Matters - Positive trial results for BRIUMVI suggest strong market potential in treating multiple sclerosis, indicating potential revenue growth for TG Therapeutics and enhancing investor confidence.